<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859129</url>
  </required_header>
  <id_info>
    <org_study_id>OM-EPA-009</org_study_id>
    <nct_id>NCT02859129</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)</brief_title>
  <acronym>ECLIPSEIII</acronym>
  <official_title>An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®), to Assess the Dose Proportionality of Epanova™, and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple Doses of Epanova™ and Vascepa® in Healthy Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the potential 2-way reciprocal interaction between
      multiple doses of Epanova™ and a single dose of rosuvastatin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PK of rosuvastatin will be monitored following single-dose administration of rosuvastatin
      with and without multiple-dose administration of 4 g Epanova™ for 13 consecutive days in
      order to detect a possible interaction between rosuvastatin and Epanova™. The PK of total
      EPA, total DHA and total EPA+DHA will also be monitored following multiple-dose
      administration of Epanova™ with and without single-dose administration of 40 mg rosuvastatin.
      A single dose administration for rosuvastatin has been judged sufficient to yield plasma
      concentrations that will be detectable with an adequate validated analytical method and
      characterize adequately the PK of rosuvastatin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ln-transformed Cmax,ss of baseline-adjusted total EPA, total DHA, and total EPA+DHA</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ln-transformed AUC0-tau of baseline-adjusted total EPA, total DHA, and total EPA+DHA</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>ln-transformed AUC0-tau of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ln-transformed Cmax,ss of unadjusted total EPA, total DHA, and total EPA+DHA</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose proportionality of baseline-adjusted total EPA, total DHA, and total EPA+DHA systemic exposure will be assessed following multiple doses of Epanova™ 2 g and 4 g</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>In Cohort 1 only, dose proportionality of baseline-adjusted total EPA, total DHA, and total EPA+DHA systemic exposure will be assessed following multiple doses of Epanova™ 2 g and 4 g using an analysis of variance (ANOVA) on dose normalized data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ln-transformed AUC0-tau of unadjusted total EPA, total DHA, and total EPA+DHA</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>ln-transformed AUC0-tau of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA using a linear mixed effect model.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ln-transformed AUC0-24 exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa®</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>The systemic exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa® will be assessed by analyzing the ln-transformed AUC0-24. In addition to an ANOVA, an analysis of covariance (ANCOVA) including the baseline value as a covariate will be performed.</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs, vital signs, ECG, laboratory tests</measure>
    <time_frame>through study completion (14 days)</time_frame>
    <description>all AEs, physical examinations, vital signs (heart rate, blood pressure, respiratory rate, and temperature), 12-lead ECGs, and laboratory safety tests (hematology, serum chemistry, coagulation, and urinalysis).</description>
  </other_outcome>
  <other_outcome>
    <measure>ln-transformed Cavg of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa®</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>The systemic exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa® will be assessed by analyzing the ln-transformed Cavg. In addition to an ANOVA, an analysis of covariance (ANCOVA) including the baseline value as a covariate will be performed.</description>
  </other_outcome>
  <other_outcome>
    <measure>ln-transformed Cmax,ss of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa®</measure>
    <time_frame>Days 1 and 24</time_frame>
    <description>The systemic exposure of baseline-adjusted (primary analysis) and unadjusted (secondary analysis) total EPA, total DHA, and total EPA+DHA following multiple doses of Epanova™ compared to multiple doses of Vascepa® will be assessed by analyzing the ln-transformed Cmax,ss. In addition to an ANOVA, an analysis of covariance (ANCOVA) including the baseline value as a covariate will be performed.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epanova®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epanova® + Crestor®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascepa®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin 40 mg tablet</intervention_name>
    <description>Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epanova™ QD (2 x 1 g capsules)</intervention_name>
    <description>Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)</description>
    <arm_group_label>Epanova®</arm_group_label>
    <other_name>omega-3 carboxylic acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose</intervention_name>
    <description>Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24</description>
    <arm_group_label>Epanova® + Crestor®</arm_group_label>
    <other_name>omega-3 carboxylic acids</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple (20) oral doses of 2 g Vascepa® every 12 hours</intervention_name>
    <description>Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).</description>
    <arm_group_label>Vascepa®</arm_group_label>
    <other_name>icosapent ethyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female (non-childbearing potential)

          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening

          -  Non-smoker

          -  Medically healthy with no clinically significant laboratory profiles, vital signs or
             ECGs

        Exclusion Criteria:

          -  mentally or legally incapacitated or has significant emotional problems at the time of
             screening visit or expected during the conduct of the study

          -  History or presence of myopathy and/or hypothyroidism.

          -  History or presence of transaminase elevations

          -  History or presence of hypersensitivity or idiosyncratic reaction to rosuvastatin, to
             other HMG-CoA reductase inhibitors, to Epanova™, to Vascepa®, or to related compounds

          -  Known sensitivity or allergy to soybeans, fish, and/or shellfish.

          -  Has consumed fish within 7 days prior to check-in.

          -  Female subjects who are pregnant or lactating.

          -  Positive urine drug and alcohol results at screening or check-in.

          -  Positive urine cotinine at screening and check-in

          -  Use of any drugs known to be inducers of CYP enzymes and/or P-gp

          -  Donation of blood or significant blood loss within 56 days prior to the first dose of
             study medication.

          -  Plasma donation within 7 days prior to the first dose of study medication.

          -  Participation in another clinical trial within 28 days prior to the first dose of
             study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Davidson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Omthera Pharmaceuticals/AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra M Connolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4425&amp;filename=OMA_EPA_009_CSR.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epanova</keyword>
  <keyword>omega-3 carboxylic acids</keyword>
  <keyword>Vascepa</keyword>
  <keyword>Eicosapentaenoic acid ethyl ester</keyword>
  <keyword>Crestor</keyword>
  <keyword>rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

